z-logo
Premium
Anti‐PCSK 9 antibodies increase the ratios of the brain‐specific oxysterol 24S‐hydroxycholesterol to cholesterol and to 27‐hydroxycholesterol in the serum
Author(s) -
Lütjohann Dieter,
Stellaard Frans,
Bölükbasi Bediha,
Kerksiek Anja,
Parhofer Klaus G.,
Laufs Ulrich
Publication year - 2021
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/bcp.14841
Subject(s) - oxysterol , medicine , cholesterol , endocrinology , evolocumab , pcsk9 , kexin , alirocumab , chemistry , lipoprotein , ldl receptor , apolipoprotein a1
Aims The serum ratios of the brain‐specific oxysterol 24S‐hydroxycholesterol (24S‐OHC) to cholesterol and to 27‐OHC reflect brain cholesterol turnover. We studied the effect of proprotein convertase subtilisin/kexin type 9 monoclonal antibodies ( PCSK9ab ) that enhance low‐density lipoprotein receptor activity on serum cholesterol and oxysterol concentrations. Methods Twenty‐eight hypercholesterolaemic patients (15 males and 13 females) responding insufficiently to maximally tolerated statin and/or ezetimibe therapy were additionally subcutanously treated biweekly with either the PCSK9ab alirocumab (150 mg, n =  13) or evolocumab (140 mg, n =  15). Fasting serum cholesterol was measured by gas chromatography and the oxysterols 24S‐OHC and 27‐OHC using gas chromatography–mass spectrometry before, after 1‐month ( n =  28) and after 3‐month ( n =  13) treatment. Results As expected, PCSK9ab treatment lowered serum cholesterol and oxysterol levels after 1 month. The serum ratio of 24S‐OHC to cholesterol increased after 1 month by 17 ± 28% (mean ± standard deviation; 95% confidence interval [CI]: 5.8 to 28%; P  < .01) and 24S‐OHC to 27‐OHC by 15 ± 39% (95% CI: 0.2 to 30%; P  < .01). Within 3 months, 24S‐OHC to cholesterol increased by 2.8 μg g −1  mo −1 (95% CI: 2.1 to 3.6; P  < .01) and 24S‐OHC to 27‐OHC by 0.019 mo −1 (95% CI: 0.007 to 0.032; P  < .01). Conclusion The serum ratios of 24S‐OHC to cholesterol and to 27‐OHC increased after treatment with PCSK9ab. We hypothesize that this is caused by a reduced entrance of 27‐OHC into the brain, increased synthesis of brain cholesterol, increased production of 24S‐OHC and its secretion across the blood–brain barrier.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here